Enstilar® - the First Combination Foam Spray for Psoriasis Launches in the UK - Seite 2

"We are delighted that there is a new, effective treatment choice now available to treat plaque psoriasis, an area of significant unmet need," comments John Warne, Founder, Psoriasis Help Organisation. "Nearly 2 million people across the UK are living each day with the significant challenges of this chronic skin condition so we welcome new options to help them take back control."

Adherence in Psoriasis Management - LEO Pharma's Solutions for Patients 

Adherence is a significant challenge for patients living with psoriasis (studies consistently suggest that up to 40% of people with psoriasis do not use their medication as directed).^[9] In recognition of this challenge and to help patients achieve optimal outcomes, LEO Pharma has developed the below suite of new resources:

• QualityCare^TM website - For more information about psoriasis visit http://www.qualitycarebyleo.co.uk
• MyPso app - For practical advice to make small changes that can have a big impact on psoriasis, download the MyPso app at the Apple App Store or Google Play
• Nurse support line - To speak in confidence to a nurse before, during and after treatment call our dedicated nurse support line on 0800 090 2165 for the UK. Lines are open Monday to Friday from 08:30-17:00

The launch of Enstilar^® is an exciting landmark for LEO Pharma, which is committed to improving outcomes and quality of life for people living with skin conditions such as psoriasis," comments Geraldine Murphy, Managing Director of LEO Pharma UK & Ireland. "This is the first combination treatment of its kind and the foam spray delivery offers a convenient new treatment option. Insights from patients show that it will be easy and convenient to use, as well as being effective and generally well-tolerated. This could be a great advantage in improving treatment adherence, which can be such a challenge for people living with long-term skin conditions."

Notes to editors 

Backgrounders on Enstilar^® and psoriasis are available on request.

Access to case studies and healthcare professionals' spokespersons for interview can be arranged.

Regulatory Approval for Enstilar^® 

The launch of Enstilar^® foam spray in the UK follows findings in the positive regulatory review of the results of the pivotal Phase 3a PSO-FAST study,^[4] which evaluated its efficacy and safety profile across a four week period, and the Phase 2 MUSE safety profile study.^[3] In the PSO-FAST clinical trial, over half of patients treated with calcipotriol/betamethasone dipropionate foam spray were "Clear" or "Almost Clear" by week 4, as measured by the Physician Global Assessment (PGA) improvement score.^[4] Additionally, more than half of patients treated with calcipotriol/betamethasone dipropionate foam spray achieved a 75% improvement in modified (excluding head) Psoriasis Area and Severity Index (mPASI) score from baseline after 4 weeks of treatment.^[4]